Nathalie Andrieu-Abadie

Dr. Nathalie Andrieu-Abadie

INSERM 1037
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Autophagy
Verified
Journal Article
Closed access
DKDaniel J. Klionsky
Daniel J. Klionsky
FAF C Abdalla
F C Abdalla
HAHagai Abeliovich
Hagai Abeliovich
RARobert T Abraham
Robert T Abraham
AAAbraham Acevedoarozena
Abraham Acevedoarozena
BJBrumell Jh
Brumell Jh
In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. A key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process vs. those that measure flux through the autophagy pathway (i.e., the complete process); thus, a block in macroautophagy that results in autophagosome accumulation needs to be differentiated from stimuli that result in increased autophagic activity, defined as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (in most higher eukaryotes and some protists such as Dictyostelium) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular autophagy assays, we hope to encourage technical innovation in the field.

22 December 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
FBFlorie Bertrand
Florie Bertrand
AMAnne Montfort
Anne Montfort
EMElie Marcheteau
Elie Marcheteau
CICaroline Imbert
Caroline Imbert
JGJulia Gilhodes
Julia Gilhodes
BSBruno Ségui
Bruno Ségui
Antibodies against programmed cell death-1 (PD-1) have considerably changed the treatment for melanoma. However, many patients do not display therapeutic response or eventually relapse. Moreover, patients treated with anti-PD-1 develop immune-related adverse events that can be cured with anti-tumor necrosis factor α (TNF) antibodies. Whether anti-TNF antibodies affect the anti-cancer immune response remains unknown. Our recent work has highlighted that TNFR1-dependent TNF signalling impairs the accumulation of CD8+ tumor-infiltrating T lymphocytes (CD8+ TILs) in mouse melanoma. Herein, our results indicate that TNF or TNFR1 blockade synergizes with anti-PD-1 on anti-cancer immune responses towards solid cancers. Mechanistically, TNF blockade prevents anti-PD-1-induced TIL cell death as well as PD-L1 and TIM-3 expression. TNF expression positively correlates with expression of PD-L1 and TIM-3 in human melanoma specimens. This study provides a strong rationale to develop a combination therapy based on the use of anti-PD-1 and anti-TNF in cancer patients.

31 July 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
AMAnne Montfort
Anne Montfort
CCCéline Colacios
Céline Colacios
TLThierry Levade
Thierry Levade
NANathalie Andrieu-Abadie
Nathalie Andrieu-Abadie
NMNicolas Meyer
Nicolas Meyer
BSBruno Ségui
Bruno Ségui
The TNF Paradox in Cancer Progression and Immunotherapy

1 May 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BLBin Liu
Bin Liu
NANathalie Andrieu-Abadie
Nathalie Andrieu-Abadie
TLThierry Levade
Thierry Levade
PZPing Zhang
Ping Zhang
LOLina M. Obeid
Lina M. Obeid
YHYusuf A. Hannun
Yusuf A. Hannun
Tumor necrosis factor-α (TNFα)-induced cell death involves a diverse array of mediators and regulators including proteases, reactive oxygen species, the sphingolipid ceramide, and Bcl-2. It is not known, however, if and how these components are connected. We have previously reported that GSH inhibits, in vitro, the neutral magnesium-dependent sphingomyelinase (N-SMase) from Molt-4 leukemia cells. In this study, GSH was found to reversibly inhibit the N-SMase from human mammary carcinoma MCF7 cells. Treatment of MCF7 cells with TNFα induced a marked decrease in the level of cellular GSH, which was accompanied by hydrolysis of sphingomyelin and generation of ceramide. Pretreatment of cells with GSH, GSH-methylester, or N-acetylcysteine, a precursor of GSH biosynthesis, inhibited the TNFα-induced sphingomyelin hydrolysis and ceramide generation as well as cell death. Furthermore, no significant changes in GSH levels were observed in MCF7 cells treated with either bacterial SMase or ceramide, and GSH did not protect cells from death induced by ceramide. Taken together, these results show that GSH depletion occurs upstream of activation of N-SMase in the TNFα signaling pathway. TNFα has been shown to activate at least two groups of caspases involved in the initiation and “execution” phases of apoptosis. Therefore, additional studies were conducted to determine the relationship of GSH and the death proteases. Evidence is provided to demonstrate that depletion of GSH is dependent on activity of interleukin-1β-converting enzyme-like proteases but is upstream of the site of action of Bcl-2 and of the execution phase caspases. Taken together, these studies demonstrate a critical role for GSH in TNFα action and in connecting major components in the pathways leading to cell death.

1 September 2001 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
NANathalie Andrieu-Abadie
Nathalie Andrieu-Abadie
VGValerie Gouaze-Andersson
Valerie Gouaze-Andersson
RSRobert Salvayre
Robert Salvayre
TLThierry Levade
Thierry Levade

1 July 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JZJie Zhou
Jie Zhou
Marcel TAWKMarcel TAWK
Marcel TAWK
FTFrancesco Danilo Tiziano
Francesco Danilo Tiziano
JVJulien Veillet
Julien Veillet
MBMonica Bayes
Monica Bayes
JMJudith Melki
Judith Melki